DNTH on Nasdaq

Magenta Therapeutics

We are a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients living with severe autoimmune diseases.1

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Galmed Pharmaceuticals Ltd., Cocrystal Pharma, Inc. or Oramed Pharmaceuticals, or pick any stock.

  • TickerDNTH on Nasdaq1
  • Industrybiotechnology industry1
  • HeadquartersCambridge, United States1
  • Websitewww.magentatx.com
  • Legal formDelaware corporation1
  • Incorporated inDE4
  • Business address7 Times Square, 43Rd Floor, New York, Ny 100364
  • Filer categoryNon-accelerated filer, Smaller reporting company4
  • LEI549300Z3N6ODPCOFC8903
  • StatusActive3
  • LEI statusLapsed (not renewed)3
  • Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States3
  • Registered withDivision of Corporations, Department of State, 57688703

See how the biggest companies compare on our leaderboards

We are a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients living with severe autoimmune diseases. Our lead clinical-stage candidate, claseprubart, is a monoclonal antibody that is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein (“C1s”) – enabling less frequent and more convenient self-administered subcutaneous (“S.C.”) injections suitable for a pre-filled pen. Additionally, selective inhibition of the classical complement pathway may lower patient risk of infection from encapsulated bacteria by preserving immune activity of the lectin and alternative pathways. We believe claseprubart has the potential to address a broad array of complement-dependent diseases as currently available therapies and those in development leave room for improvements in …5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-8739.3%Operating margin6
-7973.3%Net margin6
-67.3%Revenue growth, 20256
-32.9%Return on equity6

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development100¢$145.6M

Out of $2.0M in revenue.6 The company lost money this year.

Financial statements

Revenue786$2.0M in 2025
0$2.0M$4.0M$6.0M$8.0M2019: $0$020192023: $2.8M$2.8M20232024: $6.2M$6.2M2024+121%2025: $2.0M$2.0M2025−67%
Operating income910111286-$177.9M in 2025+114% since 2019
-$200.0M-$150.0M-$100.0M-$50.0M02019: -$83.0M-$83.0M20192020: -$78.7M-$78.7M2020−5%2021: -$74.7M-$74.7M2021−5%2022: -$29.7M-$29.7M2022−60%2023: -$48.2M-$48.2M2023+62%2024: -$101.9M-$101.9M2024+111%2025: -$177.9M-$177.9M2025+75%
Net income910111286-$162.3M in 2025+111% since 2019
-$200.0M-$150.0M-$100.0M-$50.0M02019: -$76.8M-$76.8M20192020: -$74.9M-$74.9M2020−2%2021: -$71.1M-$71.1M2021−5%2022: -$28.5M-$28.5M2022−60%2023: -$43.6M-$43.6M2023+53%2024: -$85.0M-$85.0M2024+95%2025: -$162.3M-$162.3M2025+91%

Every line of the income statement as filed: the last 2 fiscal years, latest first.6

Period ending2025-12-312024-12-31
Total revenues$2.0M$6.2M
Research and development$145.6M$83.1M
General and administrative$34.3M$25.0M
Total operating expenses$180.0M$108.1M
Loss from operations-$177.9M-$101.9M
Interest and investment income$16.1M$17.4M
Gain on investment in former related party$508.0K$148.0K
Loss on currency exchange, net-$57.0K-$64.0K
Other expense-$974.0K-$554.0K
Total other income$15.6M$16.9M
Net loss-$162.3M-$85.0M
Net loss per share attributable to common stockholders, basic-$4.20-$2.55
Net loss per share attributable to common stockholders, diluted-$4.20-$2.55
Weighted-average number of shares of common stock outstanding including shares issuable under equity-classified pre-funded warrants, used in computing net loss per share of common stock, basic38.6M shares33.3M shares
Weighted-average number of shares of common stock outstanding including shares issuable under equity-classified pre-funded warrants, used in computing net loss per share of common stock, diluted38.6M shares33.3M shares
Unrealized gain on marketable securities$383.0K$59.0K
Total other comprehensive income$383.0K$59.0K
Total comprehensive loss-$162.0M-$84.9M

Compare Magenta Therapeutics with another company

Leadership

Who has led Magenta Therapeutics, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Marino Garcia2023–now

President

  1. Marino Garcia2023–now

Chief financial officer

  1. Ryan Savitz2023–now
20202025
Board members and other officers (37)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerKenneth Evan Thompson named Apr 21, 202252

Former names

  • Magenta Therapeutics, Inc.Nov 23, 2016 to Sep 8, 20234

Timeline

  1. Sep 13, 2023New chief executive Marino Garcia becomes CEO15
  2. Jun 17, 2015Founded Magenta Therapeutics is founded3

Filings

385 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 53 major events, 141 insider forms, 76 large holders, 1 private raises, 93 other. The latest 20:

  1. Sep 18, 20264 EDGAR
  2. Sep 18, 2026S-3ASR EDGAR
  3. Sep 17, 2026144 EDGAR
  4. Sep 3, 20264 EDGAR
  5. Sep 1, 2026144 EDGAR
  6. Aug 19, 20264 EDGAR
  7. Aug 14, 20264 EDGAR
  8. Aug 14, 2026SCHEDULE 13G/A EDGAR
  9. Aug 13, 2026SCHEDULE 13G EDGAR
  10. Aug 11, 20264 EDGAR
  11. Aug 11, 20264 EDGAR
  12. Aug 11, 20264 EDGAR
  13. Aug 10, 2026144 EDGAR
  14. Aug 10, 2026144 EDGAR
  15. Aug 10, 2026144 EDGAR
  16. Aug 7, 2026144 EDGAR
  17. Aug 7, 2026144 EDGAR
  18. Aug 7, 2026144 EDGAR
  19. Aug 7, 2026SCHEDULE 13G/A EDGAR
  20. Aug 7, 2026SCHEDULE 13G EDGAR

The 385 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

32 open-market trades by officers, directors and large owners since October 2021: 7 buys and 25 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 17, 2026CARR EDWARDCHIEF ACCOUNTING OFFICERSale20,000$101.38$2.0MForm 4
Sep 1, 2026Randhawa SimratEVP, Head of R&DSale23,124$106.41$2.5MForm 4
Aug 19, 2026Read SimonDirectorSale2,778$117.55$326.6KForm 4
Aug 10, 2026McGeorge AnneDirectorSale7,750$109.01$844.8KForm 4
Aug 10, 2026Veness Adam MSVP, General Counsel and Sec.Sale16,167$110.38$1.8MForm 4
Aug 10, 2026Read SimonDirectorSale2,777$109.55$304.2KForm 4
Aug 7, 2026Veness Adam MSVP, General Counsel and Sec.Sale3,833$110.70$424.3KForm 4
Aug 7, 2026Garcia MarinoCEO AND PRESIDENTSale166,000$108.11$17.9MForm 4
Jul 9, 2026Savitz RyanEVP, CFO & CBOSale31,249$101.03$3.2MForm 4
Jun 17, 2026Veness Adam MSVP, General Counsel and Sec.Sale30,000$80.80$2.4MForm 4
Jun 1, 2026Randhawa SimratEVP, Head of R&DSale26,530$90.62$2.4MForm 4
May 8, 2026Soteropoulos PaulaDirectorSale599$85.47$51.2KForm 4
Apr 9, 2026Savitz RyanEVP, CFO & CBOSale8,224$89.84$738.8KForm 4
Mar 31, 2026Savitz RyanEVP, CFO & CBOSale114,367$83.00$9.5MForm 4
Mar 31, 2026Soteropoulos PaulaDirectorSale599$80.11$48.0KForm 4
Mar 24, 2026Soteropoulos PaulaDirectorSale27,594$78.05$2.2MForm 4
Mar 12, 2026Randhawa SimratEVP, Head of R&DSale33,830$81.48$2.8MForm 4
Mar 12, 2026Garcia MarinoCEO AND PRESIDENTSale122,918$81.49$10.0MForm 4
Mar 12, 2026CARR EDWARDCHIEF ACCOUNTING OFFICERSale43,682$81.49$3.6MForm 4
Dec 4, 2025Savitz RyanEVP, CFO & CBOSale20,000$45.18$903.6KForm 4

All 32 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Apr 6, 2022Raised $100 million in a private offering of equity Form D: 22 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Fmr LLC8,199,893$799.3M0.0%+432,207
BlackRock, Inc.4,123,822$402.0M0.0%+948,119
Wellington Management Group Llp3,229,882$314.8M0.1%+634,099
Fairmount Funds Management LLC2,537,191$247.3M16.3%No change
State Street Corp2,357,440$229.8M0.0%+958,527
Vanguard Capital Management LLC2,159,568$210.5M0.0%+128,319
Avidity Partners Management LP2,104,184$205.1M32.8%−2,104,184
Octagon Capital Advisors LP1,841,667$179.5M16.5%−105,000
TCG Crossover Management, LLC1,676,624$163.4M3.9%No change
Fred Alger Management, LLC1,302,493$127.0M0.4%+140,570
Geode Capital Management, LLC1,258,502$122.7M0.0%+342,291
Venrock Adviser, LLC1,180,000$115.0M3.5%No change
UBS Group AG1,140,260$111.2M0.0%+358,978
Deerfield Management Company, L.P.1,125,313$109.7M1.4%+105,500
Jennison Associates LLC1,021,763$99.6M0.1%+536,627
Polar Capital Holdings Plc1,018,726$99.3M0.3%−57,283
Citadel Advisors LLC974,911$95.0M0.1%−635,572
Franklin Resources Inc968,983$94.5M0.0%+801
Baker Bros. Advisors LP852,164$83.1M0.4%No change
Logos Global Management LP800,000$78.0M3.4%+400,000
Cormorant Asset Management, LP750,000$73.1M3.7%−200,000
Alliancebernstein L.P.834,150$70.0M0.0%−91,921
Braidwell LP594,562$58.0M2.2%−304,802
Vanguard Portfolio Management LLC570,115$55.6M0.0%+220,734
Assenagon Asset Management S.A.561,298$54.7M0.0%New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77